

## Transcatheter closure of post-surgical paravalvular leaks

Wojciech Wojakowski MD

Department of Cardiology and Structural Heart Diseases

Medical University of Silesia

Research, Digital and Innovation Committee EAPCI




## Disclosure Statement of Financial Interest


I, Wojciech Wojakowski: DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

## Transcatheter paravalvular leak closure





#### Transcatheter paravalvular leak closure



<b>2</b> a	B-NR	3. In patients with prosthetic paravalvular regurgitation with the following: 1) either intractable hemolysis or NYHA class III or IV symptoms and 2) who are at high or prohibitive surgical risk and 3) have anatomic features suitable for catheter-based therapy, percutaneous repair of paravalvular leak is reasonable when					
	performed at a Comprehensive Valve Center (5-9).						
Transcatheter closure should be considered for suitable paravalvular leaks with clinically significant regurgitation and/or haemolysis in patients at high or prohibitive surgical risk. <sup>547</sup>			lla	В	ACC/AHA 2020		
Decision on transcatheter or surgical closure of clinically significant paravalvular leaks should be considered based on patient risk status, leak morphology, and local expertise.			lla	С	ESC/EACTS 2021		


- HF symptoms (NYHA II-IV class) despite optimal pharmacotherapy and/or hemolysis
  - ≥ 2+ PVL jet in color Doppler mapping plus at least one of the following:

#### **Mitral PVL:**

- systolic flow reversal in at least one PV
- increased calculated PAP
- lack of left atrium (LA) size reduction after MVR or recurrent and progressive LA dilation
- forward transprosthetic flow velocity higher than expected with given prosthesis type and size, provided normal function of prosthetic leaflets

#### **Aortic PVL:**


- holodiastolic flow reversal in the proximal part of descending aorta
- lack of left ventricle (LV) size reduction after aortic valve replacement (AVR)
- recurrent and progressive LV dilation in postoperative course
- forward transprosthetic flow velocity higher than expected with given prosthesis
   type and size, provided normal function of prosthetic leaflets




## MV

## CSA in 3D TEE MPR










Technique	Benefit
Zoom mode + CD acquisition of small volume of tissue containing PVL channel only	Highest possible volume rate
Single-beat acquisition only	Avoidance of stitching artifacts
Multiplanar presentation	Measurements of CSA of VC, minimum and maximum dimensions of VC, channel length


Pysz P, Kozłowski M, Malczewska M, Adamczyk-Filipek E, Wojakowski W, Smolka G. Adv Int Cardiol. 2019;15(2):203-210.

## **Aortic PVL**











- Mother-and-a-child technique
- 6 F coronary guide catheter and 125 cm 5F coronary diagnostic catheter
- Delivery sheath (5-9F) over stiff wire
- Shadowing from prosthetic valve/3D not very useful

## **Hybrid imaging**





## **Mitral PVL**




## **IVS Puncture**










## **COMBO** technique for Mitral PVL







- Steerable sheath (8.5 Agilis; 12F Flexcath; 14F Occlutech)
- 6 F coronary guide catheter and 125 cm 5F coronary diagnostic catheter
- Delivery sheath (5-9F) over stiff wire or up to 3 coronary catheters
- Wire in the left atrium to provide distance of the tip

## **Current device selection**

Vascular plugs (AVPII, AVPIII, AVPIV) and PDA occluders (Abbott)

(AVP III – approved for PVL)







Sealing material








PLD device (Occlutech) (CE-Marked for PVL)




## **Current device selection**



oversize





Delivery	Sizes [mm]	
4F	4x2, 6x3	
5F	8x4, 10x3	
6F	10x5	
7F	12x3, 12x5, 14x3, 14x5	





Cover all anatomies (long, crescent)




Occlutech® PLD RECTANGULAR_W*						
				Introducing system **		flow Donahan
REF NO	D1 [mm]	D2 [mm]	AxB [mm]	ID [mm]	Size [F]	Flex Pusher Item no.
61 PLD 04W	11.5	10	4x2	2.21	6	50FP100L Dark Blue
61 PLD 06W	14	12.5	6x3	2.21	6	50FP100L Dark Blue
61 PLD 08W	16.5	15	8x4	2.54	7	50FP100L Dark Blue
61 PLD 10W	19	17	10x4	2.87	8	50FP100L Dark Blue
61 PLD 12W	21	19	12x5	3.20	9	50FP120L Dark Green
61 PLD 14W	24	22	14x6	3.20	9	50FP120L Dark Green
61 PLD 16W	26.5	24.5	16x8	3.40	10	50FP120L Dark Green
61 PLD 18W	28.5	26.5	18x10	3.40	10	50FP120L Dark Green


Suitable for multiplug AVP III	Suitable for single PLD
Irregular/crescent CSA of VC	Round /oval CSA of VC
Channel length >5 mm	Channel length ≤5 mm
Bulks of calcium within channel or surrounding structures	No structures potentially
that might impede full expansion of discs	impeding disc apposition










PVL crossing






Plug delivery and positioning







Plug delivery and positioning


## Multiplug approach







## PLD device



### Registry data

## Multiplug Paravalvular Leak Closure Using Amplatzer Vascular Plugs III: A Prospective Registry


Grzegorz Smolka, 1\* MD, Piotr Pysz, 2 MD, Marek Jasiński, 3 MD, PhD, Tomasz Roleder, 2 MD, Ewa Peszek-Przybyła, 1 MD, Andrzej Ochała, 1 MD, PhD, and Wojciech Wojakowski, 1 MD, PhD

#### TABLE II. Procedure Details

	Paramitral	Paraaortic		
Numer of leaks	29	20		
Numer of procedures	34	20		
Second attempt after	5	_		
failed procedure				
Transapical	9 <sup>a</sup>			
Number of leaks with	13/14/2	14/6/0		
2/3/4 implanted plugs				
CSA of simultaneously	68 [95%CI:	36 (95%CI:		
implanted in	60.9-96.0, min.	32.0-47.6, min.		
one PVL plugs (mm <sup>2</sup> )	26, maks.280)	12, max.53)		
PVL CSA (mm <sup>2</sup> )	47 (95%CI: 24 (95%			
	39.1-55.5, min.	21.2-26.8, min.		
	10, max. 165)	18.0-82.0)		
No more than mild	26	20		
residual leak after				
TPVLC				

## Transcatheter closure of paravalvular leaks using a paravalvular leak device – a prospective Polish registry

Grzegorz Smolka¹, Piotr Pysz², Michał Kozłowski¹, Marek Jasiński³, Radosław Gocoł³, Tomasz Roleder², Agnieszka Kargul⁴, Andrzej Ochała¹, Wojciech Wojakowski¹



**Figure 5.** Influence of device oversizing on residual flow presence (filled circles) or absence (empty circles)

#### Registry data

## Transcatheter paravalvular leak closure and hemolysis – a prospective registry

Grzegorz Smolka<sup>1</sup>, Piotr Pysz<sup>1</sup>, Andrzej Ochała<sup>1</sup>, Michał Kozłowski<sup>1</sup>, Wojciech Zasada<sup>2,3</sup>, Zofia Parma<sup>1</sup>, Michał Tendera<sup>1</sup>, Wojciech Wojakowski<sup>1</sup>

Variable	Reduction of CSA < 90% N = 16	Reduction of CSA ≥ 90% N = 59	<i>P</i> -value
ΔHGB <sub>discharge – 1 month</sub> [g/dl]	0.7 ±1.1 0.7 (0.2–0.9)	1.3 ±1.0 1.2 (0.5–2.0)	0.0365
ΔHGB <sub>baseline - 6 months</sub> [g/dl]	0.0 ±1.8	1.6 ±1.6	0.0020
ΔRBCC <sub>discharge - 1 month</sub> [M/mm <sup>3</sup> ]	0.2 ±0.3 0.1 (-0.1 - 0.4)	0.5 ±0.3 0.5 (0.2–0.7)	0.0007
ΔRBCC <sub>baseline – 6 months</sub> [M/mm <sup>3</sup> ]	-0.1 ±0.7 0.0 (-0.9 - 0.4)	0.6 ±0.5 0.6 (0.2–0.9)	0.0003
ΔLDH <sub>discharge - 1 month</sub> [IU/I]	48.9 ±260.5 38.0 (36.8–108.0)	8.9 ±181.4 3.0 (–88.0 – 73.0)	0.3512
ΔLDH <sub>baseline - 6 months</sub> [IU/I]	-164.9 ±577.3 -6.0 (-290.0 - 117.0)	-296.9 ±508.1 -173.0 (-487.0 - 28.0)	0.2547

Other predictors: mitral location, calcifications


# Improved Transseptal Access for Transcatheter Paravalvular Leak Closure Using Steerable Delivery Sheaths: Data From a Prospective Registry

Michał Kozłowski, MD, PhD1; Piotr Pysz, MD2; Wojciech Wojakowski, MD, PhD1; Grzegorz Smolka, MD1


Implantation time (minutes)	28.5 (15-58)	64 (35-180)	<.05
Technical success rate	29 (93.5%)	16 (72.7%)	<.05
PVL location			
Anterior	10 (32.2%)	7 (31.8%)	NS
Medial	11 (35.5%)	8 (36.3%)	NS
Posterior	3 (9.7%)	4 (18.1%)	NS
Lateral	7 (22.6%)	3 (13.6%)	NS
Procedural failures	1	2	NS
Failure to cross the PVL	1	1	NS
Valve interference	0	1	NS
Total number of implanted devices	47	42	NA
Number of implanted PLDs	29	9	NA
Number of implanted AVP III devices	18	32	NA


## Post procedural assessment and follow-up

#### Baseline




#### Post procedure





## Troubleshooting





Snares

Large deflectable sheaths

#### Conclusions

- Clinical assessment: HF, hemolysis, exclusion of infectious endocarditis
- Transcatheter closure of PVL is preferred treatment for patients with HF or hemolytic anemia
- In majority of cases multiple plugs are necessary
- COMBO approach with large deflectable sheaths improves mitral PVL closure
- Optimal toolbox (delivery sheaths, guidewires, catheters, snares)
- TOE is a must preferably with 3D reconstruction
- Residual/recurrent leak and hemolysis (PVL can reoccur)
- Incomplete closure, even if reducing HF symptoms, may result in worsening of hemolysis
- Dedicated device which provides complete sealing is needed

wwojakowski@sum.edu.pl

